Dengue Testing

Dengue Testing

Global Dengue Testing Market to Reach US$740.8 Million by 2030

The global market for Dengue Testing estimated at US$531.0 Million in the year 2023, is expected to reach US$740.8 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Hospitals End-Use, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$367.8 Million by the end of the analysis period. Growth in the Diagnostic Centers End-Use segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$143.3 Million While China is Forecast to Grow at 8.3% CAGR

The Dengue Testing market in the U.S. is estimated at US$143.3 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$161.3 Million by the year 2030 trailing a CAGR of 8.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Dengue Testing Market - Key Trends and Drivers Summarized

What Is Dengue and Why Is Accurate Testing Crucial?

Dengue fever is a mosquito-borne viral disease prevalent primarily in tropical and subtropical climates worldwide, posing significant public health challenges. Caused by one of the four dengue virus serotypes, it presents a wide range of symptoms from mild fever to severe flu-like conditions, and in critical cases, it can progress to dengue hemorrhagic fever or dengue shock syndrome, which can be fatal. Accurate testing for dengue is crucial not only for appropriate clinical management but also for controlling the spread of the disease. Early diagnosis helps in managing the symptoms more effectively and can reduce the progression to more severe forms. Moreover, distinguishing dengue from other febrile illnesses in endemic regions is essential for targeted public health responses and efficient resource allocation.

How Are Dengue Tests Conducted and What Technologies Are Involved?

Dengue testing involves several methodologies that depend on the stage of the illness. In the early stages, viral RNA can be detected using RT-PCR tests, which are highly specific and can identify the virus serotype. As the disease progresses, the focus shifts to detecting antibodies using ELISA (enzyme-linked immunosorbent assay) tests that can differentiate between IgM and IgG antibodies. IgM antibodies are typically detectable from about five days after the onset of symptoms and indicate a recent infection, while IgG antibodies appear later and can indicate a past infection or enhancement due to secondary infection with a different serotype. Rapid diagnostic tests (RDTs) have also been developed, which are invaluable in resource-limited settings for their ease of use and quick turnaround times, although they generally offer less specificity than laboratory-based tests.

What Are the Challenges in Dengue Testing?

Despite advances in diagnostic technologies, dengue testing faces significant challenges. One major issue is the cross-reactivity with other flaviviruses such as Zika and chikungunya, which can lead to misdiagnosis. This is particularly problematic in regions where these viruses co-circulate. Another challenge is the variation in test sensitivity and specificity, especially among rapid diagnostic tests, which can lead to false negatives or false positives. Such inaccuracies can have severe implications for patient care and disease surveillance. Additionally, the window for detecting the virus or antibodies is relatively short, which necessitates timely testing that may not always be feasible in remote or underserved areas. These challenges underscore the need for ongoing research and development to enhance the accuracy, accessibility, and reliability of dengue testing methods.

What Drives the Growth in the Dengue Testing Market?

The growth in the dengue testing market is driven by several factors, beginning with the rising incidence of dengue worldwide. As global travel increases and climatic conditions favor mosquito breeding, dengue is expanding beyond traditional geographic boundaries, increasing the demand for diagnostic tests. Public health initiatives focused on controlling the spread of dengue also fuel this demand, particularly in endemic countries that are implementing more rigorous surveillance and control measures. Advances in biotechnology that have led to the development of faster, more accurate, and cost-effective tests are also significant growth drivers. Additionally, the growing awareness of the economic and health impacts of dengue has led to greater public and private sector investment in preventive care and diagnostics. Finally, the COVID-19 pandemic has heightened global attention on infectious diseases and the critical role of timely and accurate testing, further accelerating investment and innovation in the field of dengue diagnostics. These technological, economic, and social drivers ensure robust market growth, reflecting an increasing emphasis on improving public health infrastructure to manage dengue and other vector-borne diseases more effectively.

Select Competitors (Total 12 Featured) -

• Abbott Laboratories, Inc.
• Abnova Corporation
• Certest Biotec S.L.
• Euroimmun AG
• InBios International
• NovaTec Immundiagnostica GmbH
• OriGene Technologies, Inc.
• Quest Diagnostics, Inc.
• Roche Molecular Systems Inc.
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.